HEALTH● LOWJul 23 · Jul 23, 2026, 10:45 AM
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
CNBC
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH56m agoNicole Sudmalis : Uncovering hidden ADHD , autism in women | Daily Liberaldailyliberal.com.au · AustraliaHEALTH56m agoUpstate University Hospital opens after - hours pediatric behavioral health center in CNYcnycentral.com · United StatesHEALTH1h agoCritical care paramedic with abseiler who suffered head injuries in fallsouthernhighlandnews.com.au · AustraliaHEALTH1h agoASTRO to Showcase Advances in Radiation Medicine and Cancer Research in 2026 Annual Meeting Press Programnewswise.com · United States